Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$18.52
-1.4%
$16.37
$8.02
$19.08
$9.33B1.6210.07 million shs5.25 million shs
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
$2.60
+0.4%
$2.55
$1.83
$7.48
$2.45B0.38.67 million shs7.70 million shs
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
$14.08
-2.3%
$11.86
$8.73
$14.48
$9.84B1.156.26 million shs7.59 million shs
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
$106.43
+0.0%
$104.80
$27.54
$106.45
$8.71B0.141.25 million shs918,692 shs
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
-1.45%+0.66%+3.85%+33.99%+27.88%
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
+0.39%+8.33%-7.80%-15.31%-28.18%
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
-2.29%+8.98%+17.74%+24.38%+13.73%
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
+0.03%+0.11%+1.17%+15.43%+253.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$18.52
-1.4%
$16.37
$8.02
$19.08
$9.33B1.6210.07 million shs5.25 million shs
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
$2.60
+0.4%
$2.55
$1.83
$7.48
$2.45B0.38.67 million shs7.70 million shs
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
$14.08
-2.3%
$11.86
$8.73
$14.48
$9.84B1.156.26 million shs7.59 million shs
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
$106.43
+0.0%
$104.80
$27.54
$106.45
$8.71B0.141.25 million shs918,692 shs
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
-1.45%+0.66%+3.85%+33.99%+27.88%
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
+0.39%+8.33%-7.80%-15.31%-28.18%
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
-2.29%+8.98%+17.74%+24.38%+13.73%
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
+0.03%+0.11%+1.17%+15.43%+253.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
2.78
Moderate Buy$17.33-6.39% Downside
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
3.20
Buy$10.75313.46% Upside
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
3.50
Strong Buy$17.6725.47% Upside
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
2.14
Hold$109.002.41% Upside

Current Analyst Ratings Breakdown

Latest IBRX, ELAN, ROIV, and VRNA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/10/2025
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$8.00
9/8/2025
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
D. Boral Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$24.00
9/2/2025
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOverweightBuy$16.00
8/26/2025
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
D. Boral Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$24.00
8/20/2025
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-BuyHold
8/14/2025
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
D. Boral Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$24.00
8/11/2025
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetNeutral$12.00 ➝ $18.00
8/8/2025
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$18.00 ➝ $19.00
8/8/2025
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold
8/5/2025
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
D. Boral Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$30.00
7/25/2025
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
D. Boral Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$30.00
(Data available from 9/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$4.48B2.05$2.22 per share8.33$12.33 per share1.50
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
$14.74M166.74N/AN/A($0.57) per share-4.56
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
$29.05M330.98N/AN/A$7.45 per share1.89
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
$221.67M39.29N/AN/A$2.56 per share41.57
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$338M$0.8621.5320.813.499.68%7.04%3.45%11/6/2025 (Estimated)
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
-$413.56M-$0.48N/AN/AN/A-648.57%N/A-113.86%11/11/2025 (Estimated)
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
-$171.98M-$0.70N/AN/AN/A-2,111.79%-15.90%-14.95%11/11/2025 (Estimated)
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
-$173.42M-$0.99N/A3,547.67N/A-36.62%-21.12%-9.07%11/3/2025 (Estimated)

Latest IBRX, ELAN, ROIV, and VRNA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2025Q2 2025
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$0.1989$0.26+$0.0611$0.02$1.19 billion$1.24 billion
8/6/2025Q2 2025
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
-$0.01$0.13+$0.14$0.13$90.41 million$103.14 million
8/5/2025Q2 2025
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
-$0.10-$0.10N/A-$0.10$21.95 million$26.43 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
N/AN/AN/AN/AN/A
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
N/AN/AN/AN/AN/A
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
N/AN/AN/AN/AN/A
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
0.61
2.60
1.40
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
N/A
4.11
3.98
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
N/A
40.54
40.54
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
0.87
10.71
10.54
CompanyEmployeesShares OutstandingFree FloatOptionable
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
9,000496.81 million492.39 millionOptionable
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
590945.26 million219.39 millionOptionable
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
860682.88 million609.13 millionOptionable
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
3081.83 million82.34 millionOptionable

Recent News About These Companies

Here’s What Boosted Verona Pharma plc (VRNA) Share Price by 49%

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Elanco Animal Health stock logo

Elanco Animal Health NYSE:ELAN

$18.52 -0.26 (-1.40%)
Closing price 09/12/2025 03:59 PM Eastern
Extended Trading
$18.69 +0.17 (+0.94%)
As of 09/12/2025 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

ImmunityBio stock logo

ImmunityBio NASDAQ:IBRX

$2.60 +0.01 (+0.39%)
Closing price 09/12/2025 04:00 PM Eastern
Extended Trading
$2.60 0.00 (-0.19%)
As of 09/12/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.

Roivant Sciences stock logo

Roivant Sciences NASDAQ:ROIV

$14.08 -0.33 (-2.29%)
Closing price 09/12/2025 04:00 PM Eastern
Extended Trading
$14.04 -0.04 (-0.25%)
As of 09/12/2025 07:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.

Verona Pharma PLC American Depositary Share stock logo

Verona Pharma PLC American Depositary Share NASDAQ:VRNA

$106.43 +0.03 (+0.03%)
Closing price 09/12/2025 04:00 PM Eastern
Extended Trading
$106.19 -0.24 (-0.23%)
As of 09/12/2025 06:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. The company was incorporated in 2005 and is headquartered in London, the United Kingdom.